A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Latest Information Update: 02 Oct 2024
At a glance
- Drugs Bemarituzumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORTITUDE-101
- Sponsors Amgen
- 26 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2023 According to Zai Lab media release, the first patient in the mainland China portion of this study has been enrolled in July 2023.
- 14 Aug 2023 Planned End Date changed from 16 Oct 2026 to 18 Aug 2025.